Clinical Trial Update: Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression [Phase 2]

View source ↗

Summary

Phase 2 study of SAGE-547 in women with severe postpartum depression has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Depression

Drugs mentioned

• SAGE-547 (brexanolone)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Postpartum Depression | Phase 2 | Status: COMPLETED | Results posted: 2021-12-02